期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
虚拟现实技术在装备培训中的应用研究 被引量:1
1
作者 李魁星 赵东波 张大鹏 《价值工程》 2018年第20期200-203,共4页
本文探讨了虚拟现实技术在装备培训领域的应用,分析了装备培训内容对培训方法手段的依赖度,设计了采用虚拟现实技术开展装备培训的基本运作流程。
关键词 虚拟现实技术 装备培训 依赖度
下载PDF
Original article :Identification of seven novel mutations in the factor Ⅷ gene in 18 unrelated Chinese patients with hemophilia A 被引量:2
2
作者 HUA Bao-lai YAN Zhen-yu +6 位作者 liANG Yan YAN Mei FAN lian-kai li kui-xing XIAO Bai liU Jing-zhong ZHAO Yong-qiang 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第3期305-310,共6页
Background Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by decreased activity of factor Ⅷ(FⅧ) due to heterogenous mutations in the FⅧ coding gene (F8). The type of mutation plays an imp... Background Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by decreased activity of factor Ⅷ(FⅧ) due to heterogenous mutations in the FⅧ coding gene (F8). The type of mutation plays an important role in the FVIII inhibitor formation. To date, several studies on the spectra of F8 defects have been performed in Western populations, but similar studies in Asian races are scarce. Here, we reported the distribution of the F8 gene mutations in 18 unrelated Chinese patients with HA. Methods Intron 22 and intron 1 inversions in the F8 gene were screened in 158 unrelated patients with HA using a long-distance PCR and multiplex PCR method. Direct sequencing of the coding region of the F8 gene was used to identify the mutations responsible for HA in 18 unrelated Chinese HA patients who were negative for intron 22 and intron 1 inversions; sequences were compared with the HAMSTERS database. A clotting method was used to assay the FⅧ activity level and the Bethesda assay was used to detect the FⅧ inhibitor. Results A total of 18 different HA F8 mutations were identified, seven of which were described for the first time. These novel mutations included five small deletions, one point mutation and one small insertion. One novel mutation (4382-3 AC deletion) was associated with inhibitor development. Conclusion These data extend our insight into the mechanisms by which novel amino acid mutations may lead to HA and how the HA patient genotypes influence the risk of FⅧ inhibitor. 展开更多
关键词 factor gene mutations hemophilia A SEQUENCING
原文传递
血友病B患者接受人凝血酶原复合物按需治疗后四种凝血因子体内回收率的观察 被引量:2
3
作者 华宝来 李魁星 +1 位作者 赵永强 郭扬 《临床药物治疗杂志》 2022年第11期17-21,共5页
目的评价人凝血酶原复合物(PCC)治疗出血发作的血友病B(HB)患者中凝血因子(F)Ⅱ、Ⅶ、Ⅸ和Ⅹ的增量和体内回收率(IVR),以验证PCC中上述因子的含量,为HB治疗提供依据。方法选取2016年10月至2017年6月期间在中国医学科学院北京协和医学院... 目的评价人凝血酶原复合物(PCC)治疗出血发作的血友病B(HB)患者中凝血因子(F)Ⅱ、Ⅶ、Ⅸ和Ⅹ的增量和体内回收率(IVR),以验证PCC中上述因子的含量,为HB治疗提供依据。方法选取2016年10月至2017年6月期间在中国医学科学院北京协和医学院北京协和医院等医疗机构参加临床试验的急性关节出血中重度HB患者,根据严重程度首次静脉注射20~40 U/kg PCC,在PCC输注前、输注后15 min采集静脉血,采用一期法测定FⅡ、FⅦ、FⅨ、FⅩ活性,计算4种凝血因子IVR;采用四点评分量表评价PCC的临床效果。结果共有69例男性患者纳入本研究,中位年龄为33岁(年龄范围为18~65岁);PCC输注剂量平均为(22.1±2.4)U/Kg,FⅡ、FⅦ、FⅨ、FⅩ的IVR分别为(1.77±0.52)、(1.63±0.85)、(1.82±0.52)、(1.80±0.61)(U/dL)/(U/kg);输注后8 h,反应优良(ER)率+良好(GR)率为88.4%(优良45例+良好16例);在输注后72 h升至100%(优良47例+良好22例);未观察到包括动静脉血栓、溶血、过敏反应和产生凝血因子抑制物等严重不良反应。结论该PCC为四因子PCC,IVR高,是一种治疗HB安全、有效的药物。 展开更多
关键词 凝血酶原复合物 血友病B 凝血因子 四因子 增量回收率
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部